<SEC-DOCUMENT>0001193125-13-357124.txt : 20130904
<SEC-HEADER>0001193125-13-357124.hdr.sgml : 20130904
<ACCEPTANCE-DATETIME>20130904170306
ACCESSION NUMBER:		0001193125-13-357124
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130903
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130904
DATE AS OF CHANGE:		20130904

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		131078494

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 430
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 430
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d593084d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Date of Report (Date of earliest event reported): <B>September&nbsp;4, 2013 (September 3, 2013) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in Charter) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><B>000-22873</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><B>36-3855489</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(State or Other Jurisdiction</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">of Incorporation)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">(Commission File Number)</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(I.R.S. Employer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Identification No.)</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Address of Principal Executive Offices) (Zip Code) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(720) 940-2200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Registrant&#146;s telephone number, including area code) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Former
Name or Former Address, if Changed Since Last Report) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;3, 2013, the Board of Directors (the
&#147;Board&#148;) of ARCA biopharma, Inc. (the &#147;Company&#148;) elected Robert E. Conway as a director of the Company to fill a vacancy on the Board. Mr.&nbsp;Conway was elected for a term expiring at the Company&#146;s 2014 annual
stockholders&#146; meeting. Mr.&nbsp;Conway was also appointed to serve on the Board&#146;s Audit and Compensation Committees. A copy of the press release relating to Mr.&nbsp;Conway&#146;s appointment is attached hereto as Exhibit 99.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mr.&nbsp;Conway served as the Chief Executive Officer and member of the Board of Directors of Array BioPharma from 1999 to
2012.&nbsp;Array is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.&nbsp;Prior to joining Array,
Mr.&nbsp;Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999. There he managed a network of company-owned research centers, conducting clinical trials for pharmaceutical and biotechnology
companies. From 1979 until 1996, Mr.&nbsp;Conway held various executive positions for Corning Inc. including Corporate Vice President and General Manager of Corning Hazleton, Inc., a contract research organization. Mr.&nbsp;Conway serves as the
Chairman of Wall Family Enterprise, a leading library and education supplies company.&nbsp;He is on the Board of Directors of PRA International, Inc. and eResearch Technology, Inc.&nbsp;In addition, Mr.&nbsp;Conway is a member of the Strategic
Advisory Committee of Genstar Capital, LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with his appointment, and pursuant to the Company&#146;s
previously adopted director compensation policy, the Company granted Mr.&nbsp;Conway an option to purchase 1,250 shares of common stock at an exercise price of $1.33 per share, the closing price of the Company&#146;s common stock on
September&nbsp;3, 2013. The option is subject to the terms and conditions of the Company&#146;s 2004 Equity Incentive Plan, as amended (the &#147;Plan&#148;), and the Company&#146;s standard forms of Option Grant Notice and Option Agreement for the
Plan, copies of which are filed as Exhibits 10.38 and 10.36 respectively to the Company&#146;s Annual Report on Form 10-K filed on March&nbsp;26, 2009. The option vests in three annual installments on the annual anniversary of the date of grant,
assuming Mr.&nbsp;Conway&#146;s continued service on the Board for such periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with
Mr.&nbsp;Conway&#146;s election, Mr.&nbsp;Conway and the Company also entered into an Indemnity Agreement in the same form as has previously been entered into with the Company&#146;s other directors.&nbsp;The Indemnity Agreement generally requires
the Company to indemnify Mr.&nbsp;Conway against liabilities incurred in the performance of his duties to the Company to the maximum extent permitted by Delaware corporate law and the Company&#146;s certificate of incorporation and bylaws.&nbsp;The
Company&#146;s standard form of Indemnity Agreement is filed as Exhibit&nbsp;10.52 to its Annual Report on Form 10-K filed on March&nbsp;26, 2009. </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="3%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">99.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;Robert E. Conway Appointed to ARCA biopharma Board of Directors&#148; dated September 4, 2013.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: September&nbsp;4, 2013 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARCA biopharma, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christopher D. Ozeroff</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3">Name: Christopher D. Ozeroff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3">Title: &nbsp;&nbsp;SVP and General Counsel</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="3%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">99.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;Robert E. Conway Appointed to ARCA biopharma Board of Directors&#148; dated September 4, 2013.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d593084dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g593084g50c56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ROBERT E. CONWAY APPOINTED TO ARCA BIOPHARMA BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><I>Broomfield, CO, September&nbsp;4, 2013</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing
genetically-targeted therapies for cardiovascular diseases, today announced that Robert E. Conway, has been appointed to the Company&#146;s Board of Directors. He will serve on the Audit and Compensation Committees of the Board of Directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Mr.&nbsp;Conway has over 30 years of executive leadership experience in the pharmaceutical and biotechnology industries. From 1999 to 2012, he
served as the Chief Executive Officer and member of the Board of Directors of Array BioPharma, a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with
cancer and inflammatory diseases. Prior to joining Array, Mr.&nbsp;Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999. There he managed a network of company-owned research centers,
conducting clinical trials for pharmaceutical and biotechnology companies. From 1979 until 1996, Mr.&nbsp;Conway held various executive positions with Corning, Inc., including Corporate Vice President and General Manager of Corning Hazleton, Inc., a
contract research organization. Mr.&nbsp;Conway serves as the Chairman of Wall Family Enterprise, a leading library and education supplies company. He is on the Board of Directors of PRA International, Inc. and eResearch Technology, Inc. In
addition, Mr.&nbsp;Conway is a member of the Strategic Advisory Committee of Genstar Capital, LLC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;We are honored to have Bob join
the ARCA Board of Directors,&#148; said Dr.&nbsp;Michael&nbsp;R. Bristow, President and Chief Executive Officer of ARCA. &#147;With his significant experience in leading both drug development efforts and companies in the biopharmaceutical sector,
Bob will be a valuable addition to the ARCA Board as we continue the development of Gencaro and look to deliver value to our stockholders.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">&#147;I am delighted to join the Board of ARCA at this important point in its development, both for the company and for the cardiology
patients we hope to serve,&#148; said Mr.&nbsp;Conway. &#147;We believe there is an unmet medical need for new atrial fibrillation treatments. The GENETIC-AF trial, conducted with the collaboration of Medtronic, will hopefully provide important new
data for the atrial fibrillation community.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>About ARCA biopharma </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product
candidate, Gencaro<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified
common genetic variations that it believes predict </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for
support of the Phase 2B portion of the GENETIC-AF trial. For more information please visit <U>www.arcabiopharma.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>Safe Harbor
Statement </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private
Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential impact of the comparative effectiveness GENETIC-AF trial, the potential for genetic variations to predict individual
patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention
treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many
factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; results of
earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of
competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended
December&nbsp;31, 2012, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Contact:
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Derek Cole </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Investor Relations Advisory Solutions </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">720.940.2163, <U>derek.cole@arcabiopharma.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g593084g50c56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g593084g50c56.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`30#9`P$1``(1`0,1`?_$`+P````&`P$!````````
M```````&!P@)"@$$!0,"`0$```<!`0$``````````````0,%!@<("0($"A``
M``8!`P(#!00)`@4%`````0(#!`4&!P`1""$2,1,)05$B(Q1Q,F(5\&&!D;%R
M%A<*H=%"4C,D-8)#-$0E$0`!`P($`@8$"`H+`````````0(#$00A$@4&,0=!
M46$B$PAQD2,4@;'!X3(D%@FAT4)2DK,5=38X\/%BPC-3<]-4A!?_V@`,`P$`
M`A$#$0`_`+VF3<F5C$]8>6ZW/@9Q30")D332,X>OWBHB#>/CFI#`=R[<&\`#
MH4`$1'8-8_YD\S=I<JMM3;GW=.D-C$U51,*O5$^BVO3Z^)5-'T34MP7S-.TM
M$6X<N*KP1/Z>DC0LWJ%Y"D9!5.CTRN0T<"J@-!L(/9F171*`['<$9/HQJ@)A
M#?9,5-O`??KE;O?[R?>D^HNDY>:590Z%GRL?>12RN=C2O<EA3$SI8<F]/MXD
M=K4DZR4[V1S6HB]E6N^,T4>;G(14$S_E&/O+6("B>T!,`(EW$H]1LFWWBCJA
M1>?GS'7%MXD-GMQ9%X?4[FGP_72?#RPV4Z7)))>(G^HS_;-Y?F=R(030,,30
M1%PU^I)W5R8(4"^>LE]X;)U_Z8?;JHZAYZ?,I9VL-Y[EMWPIK97I6SN?IHKD
M_P";PP3#CVD(N6.R7R3,=)>48F'M&?A]D<9SSJS\P,D+J'H)BB`'.0L#+D[R
MB80[2*#8Q`I_A]H#JFS_`'@7F"T]S??[3;M,B.5J6ERCJ=GUQ?B/HBY2[2N7
ML9;R7G>97&1G&JI_E]@X["7..%OTPRJE]BV=.G9!9-K&R;=PJM7Y!VMN5)FL
M+L$G,4Z44#8OF"=(QA``/K:KD-Y\MJ\QM0MMK[QMTLMPW#\B2,1609L*(J/5
MRI5<$[Y9&[N5%]H,#]0L7++9,HJHM%<B+Z$2OJ0?@1T8Q=Q[2B`F`0V'<-NN
MP]=A-L/7;IKH(M6-61:.C545JITM5$^?X##V*(Y[L(V\3T\\_N+^X?\`?7H]
M<<4X`\\_N+^X?]]`)CEK-N,<$U0MXR[=8*AU12?@:NG.3ZKALQ//VF32B("+
M(9)!=51R_?+E(':42E*!CG$I`$0`4I-PH8!$1(8-PVV#IL)0,`@(&$!*(&Z#
M[0ZZ`]///[B_N'_?0"<Y)S/BK#<9'S66\DT3&,/+/_RJ*E;Y:(BJQTE)^0JY
M&/9NYEVS0</`;(G4\LIQ.)2^&W70!#9\N>+DBB*['DG@)RD`=WF)Y:HXD[?'
M?_S@=-O;H`O/N<_#6,7^FD>5G'9HX$>T$5<OT<IP$!$/`9H?:&@%EHF6L;Y1
M:&D,:Y"HF06!"@HH[I5K@[.@DB?HF=8T-(/#(=QM@^,"AUZ:`/WGG]Q?W#_O
MH`>>?W%_</\`OH#A62VUZFQ#JQ6^?@ZO7F)!4?3=AE&,)$LR!ON=U)2;ILS1
M#8.@&.`CL.V^@&,SGJM^GE7I1U#/.5V,)*09&$KQ&I#8KRFV$#"`E6=TV$GF
M:8AMU`5-]`;-:]5#T];<Z^AAN7.&DGF^QF\_-/*FLF.P#LLE:F<*9'Q_X^WW
M:`>)0,G4+*D`%KQI=ZCD&L&=+L2V"F3L?8H<7S42_5,1?Q;ATV([;%63%1,Q
MP.3?J'70!V\\_N+^X?\`?0&#+J;#V@F(["(=W<!>@?\`$(=VP:`3!IF[&3_+
MDS@9E=(%QF&OTN.R+,T`BZPSL?29>06BHVPN2`B+8C-U()>6!04%8H"4QB=I
MRB("G@N<0`=BCN`#OL/7<-]_'VZ`^BK&$P!L7J(!X#[1^W0&SH"(_P!0N?D7
M.1J-5O/[(N-JAIU-J;?R5Y&4EWC$ZRFP;`9%G&=I=_\`G'7'G[R+=.MNWKI.
MS'R.3;#=,CNG,HN5TKKB=BU6M/HQLPH;`<H=,M_V;+JZKEG2Y5E>G*C&+_>4
M;5CO'Q+$LBU%1%N_7$OY>HX[?IG`FZ$9F4W\M(RANA!$=NX>HAK3WECRY^V]
MS(Z9N:1Z>Q1%]FW*E:*M,%7H[2_-P:W[D_.Q[GV"_2P[R.7!M&]*5XK7!!U]
M7Q`+Z%F(M:-.A-5HWYHBT71%-=6/*(MYEJ)#B`>8W.5-9$=QZ;[;]VMW-G\E
MK>?;MY9.ME3<-I$K_#<E'/:B5]GA5ZX<$0QG?;B6&1LR/I$Y?ZL.T4%_A4DD
MK2VOD`U:*U)L]D7(HB`-F;1V_<.SF$1`"G%LH`%`=A$PA[M94UWD/'<V^@6C
M;-S+1MBY]PYZ94C1'/<[Q%IW<.%>)2;?=2I-.JJZKURM]*_%Q&]W3&`2A92=
M,V0C(=-PX`BYDA%$"B8091+`I!W>NP;%#8`[BI``B;6KN^^3<6H75WN>PA>F
MB-58XI%2C7(Q,53H7O5Z<2_=(UN6%C(7/3QJ5P6N%1H%EAUHU=11$ID4P`#(
M%#YGE]@[%.4Y>@*>T!Z;#K2;6[:ZT+4U]S>Z*]@E26-42F,2YT[WP&1[5\-W
M;N]]>KHW,5*<<52B$^&#;$^MN(<=6*3-YTA*56,.^6-T.LX11!HLN;;Q.L=O
MW#]NOT:\A]T7^Z^3FWMQW??N+FP1SE5:*N17,[<>Z:=;JMF6>N7.EV^$2/7U
M+B*QK+U:XE%1*)3J!H1*D7^0KFZVY)M45@2A-I)[CGC@2K7O.<Y&G\R+ALCY
M9![$XOB)A0HAV*Q\&Q<K(@._:O($$>I-`3J^ESR9+RGX3X>O\B]([NE:B!QI
MD4/,*HX"Y4--"&=/'(`/<5:=C2-I#8=O_E#MX:`D(_3KH`G7;'E"R5$_D.1*
M13[[!E5!<D-=:U#6F+!<2G2,L5C-L7[9%8$3B4#D*!]C"&^@*('K8\>,0\=.
M:TG5<,TB#H%6LF,Z=>5:O`,DVM?B[!+.9^/E'$0P$5$HUF]5CB+&;)%*B17J
M0I0$0T!;WXY<#.&-,P=C:$C^,F$GQ'>/ZDXE9.?QO5;'.SSZ1K\<]D9&9FIR
M-?R+UT]=KG.83JF`!'8NQ0```KV>LIQ%K?`3(N%N5O#9U)\?7-[L4M7+#!XU
MDGU?C(JY131.9C9V#8-5P:LXZ;C2K(/(S86!CHE^4)3&+H"P9Z8_+&9YF\0,
M?YAMB#1"_-GDU1<AC'MQ:1[VW5%R1F\F&3,=_HD)QDH@[%$/A3.L8I=B@`:`
M[?/WG3CW@9@]WDVTM0LEPGG2U=Q;CY%X1F\NEJ\DRI@6<;F58UV$1#ZB1=%(
M84D0`I`,=0@"!`MPHXM9V]8*U/N67/6]V2<X\0E@<Q^-L,0;^3J]+MLI'+@5
MXVAH=L8&\708,VS99X3S).5<$4(=8A2',(%G[&V%,08?KK2IXNQ?0\?5MDV3
M10AJE586&0`$R=H>>9JS(H[5';<RBQE%#&W$3FT`VKEAZ=W%KF+4I6$R;C6N
MQ=M<,W*=?RI586+A<@U>252$&\@WF&;9+\X:I*C\UF^!9NL3<!*41`Q0&0>B
MCB^V\9X3F#P_OBK1Q8L#\A$)-E(M$3-FMBJV1:?&/J[:V#<QNY-I/,88%A*;
MN,DN*J8CT`=`3B:`+UNM<!1*K9;M;'Z416*?7YBT6"5<CV(1T+`1[B4DWJAO
M85NS:G-[QVZ==`47L:\W<H4#U6*9S/RM'S52K>?Y^/D7,=,=R:`<9<I+&J=+
M=-PZC^45^OQS.0(8VP^<R,I_Q:`O?E4(H!#IG*J10.XJB0@9,Q!#<JA3`(E%
M-0!#M$!$!`0VZ:`]2??+_,7^(:`WM`1&\Y4SCGBJ')X_V]C2_$4%"_\`G[#_
M`.V<#$$>ONUQ;^\(9XWF"TB)9,K/LW!@[_#7ZY><>WYC8KE7!(_:%Q*Q<$O'
M?JXS;Q?%UQZDT;R\7(,U#@"9Y*OIE.!=Q#<'<,J18')""._F-U$Q'W:NGE%I
M&UK[2X-,O[>7/*K42:WPR.5>ZY<%P1<5Q3#I*7KL]XV21D5%5$7!1P-KR&XK
MMAB:+`.T7,Y'P[=>8MZS(K>52C9(AE(R'3*OW*'4!J4AE5%`,*8"4``!ZZV5
MW?S+@T#7;;E]L^YM[K4+:T19KNGM(VJBX.HN-$3I5"S].T.2[LIM1U!52%'+
M1.BJ<5]8KE?;3"T*J\<3:[LAFQB.6<@N9=!VF8OQH*`;;L*H`[?`)=O9MK+F
MU&ZO!MQ=9O[MT\LK?:12<)8NE$QX*E>LI&I20MD3W=$14I2B=/7Z0@9'C:Y+
M,&$Q(+R0QR;0Y(FMP<<1NWCSH@9)UWR(IK-T167(;N4!(5!*(`/35B<TM#VK
MJNCQ:I?NE;IK8:16T%$8RCE7*[CWLRJJX<%0^O29KILR(BXUQ55X_!\7!.HC
MFRTU;G^J.RC&T>@3<@);F<N3`'4HJO%^U980_`4@![0VURFYX6FEM66:UM_=
MG,148B\7(O%>"=!G/;LTSU8UZU;0E=XR@8,"8N`VP"%70Z!T_P#LN==G/*O_
M`"Z[4_=COULIKKO/^,;OT_(+KK8%.!;J\1,<TY8JV"<39%S'=71&E6QI3YRX
MS*ACE(*C:%8K.DV*1C;A]5)NB)MD0V'N55*&HD"&#BCP^F.3?IP\D;3F!D!<
MR>HB\MN=Y%V_1*+F"7<&.[P1&`10H*)MJTTC6CA$@;%(FY$"_>$1`C=_QX^0
M4AB_/N6^)%Z6<1?]R&+FPP<.]/VC'95QJ=U&6N'2(?M33?2L""@J%^\8T67K
M[-`7#_\`7]?C_J'0=`#0%'S_`"']@YZL!,)0`,!8_$1,;M#8)ZV[AOL.V^@+
MG6*G35MB#&;M=RU0:$QO2E%7+ARFBW12+5HH1447/LDF4@==S"`"`^.@*RWK
M:YA+S5R?@CA3Q,8K9XR%3['-7&\ACPQ)^)@)J1CR0,+#2M@8F/7XWZ!N=TYD
M'*S@B#(O:4QA.!B`!.5Z<G$97A/Q1HF$926;3MQ(ZE;?D&58&4/&KW:SK)N9
M9I$G6(596,B4DD6B*ANJI4>_8.[8`*GOKI9?L&:?4#FL4-Y!<8##L72L85..
M*<#I-;#;$(V=LT@D@38A73^4FFB1C"'<)69"^!=M`73<!8H@<%X2Q5A^M,$H
MV'QW0:W5&Z+<@(E.O'1K<DD[$"`79>0DO.75-XG45,(^.@%=T`-`:R;)HBX6
M=HMFZ3IR!`=.4T4B+NBI`8$".5BD!5<K<IA!,#"/8`B`;!H#9T!#GZN&0+!=
M8'!OI^8S?F;Y#YNY$C:A:'#%8_UE5P977[.8R78A\H06;H/6#<6H'-\*B)5R
M^_0$=_\`D)<1X*!PYQRSECR!2CH;#[6/X\6!)B4J1FM!>LTQQRLL9+L3,A"S
M,>X;$$0'XY$@>W;0$MOI(\F#<G^#V([)*R'U]WQ^R/B3((J+><Z/8Z(V;,64
MFY'JJ*LW65&3L3GV$PK&'J(Z`DQ)]\O\Q?XAH#>T!$MS<>+M<\U7R%%4S#C^
M)/NB(`I\-AL(C\0[[=`UQL\^][+9>8;1Y(EJOV<@[O\`W+S$V!Y8-MG[4N&3
M(JN6\=ZO#C#GB>RSS5JT-)7MQ7V9NP$VYW0OY-4"&!02-XI$7/E"H`;;K=A=
MNNLH\G=SZS;6$-_>:XFGZ:QBHYD:(LBHJ<&IF3%>!0-PZ7;2/=EB=(KERHG4
MJX(M>SCP-7.,#8F%J9YDK;&9GZK88QFQG7";$5I*/?1:)&A9=S&-`5.M%2+5
M,#^<1,2HJE$#``#OJF^8':NY-N;MAYS;6AO=2VGJ%LQ9GL:JW35CKF5K41<%
M/JVQ<VON$VWM4E2"]BQB7HJN*)7#'L/>I9=DK*5K!UQO(S$BZ$$BLFZ2AE0,
M8HF'SQ$`2:`!0$3'4$A2AU$=>]C\W)=VPMV[MAEU+J\C/#=6-7*C'?2JB*E%
M2JHO:A)UG0+'3HEF61KJI7Y1?YJ2<5&NLJTZN#RL3Z+$SYX!V9Q@I!R__P"X
M5*D_:MW3A%%!57RO,``+N7?;KK9/7;S[)[>M-M?M6YTW7FVR/2%T:,AD:YSO
M:+5ZK575:J]*-+-LF6]S=>)[MXD=:(J<<.CM^0CRS-.V%0[@DC*KO2F*8I'3
M:0!\U4$NQA['B0G2`!#V&V-[-@'7,/S!ZQN"XOI++5[EES&YJJCF)W<*JE5K
MQ,X;8MK:-['Q6ZQN1JX_`2A\9SB?`V,#&W$1K"'4>HC_`-PXZCKKWY7/Y>=J
M_NQWZV4U^WE_&-UZ?D%TZ^P!'K[/9^L?U!K/R<"W5XD%/K!66U9_M_&OTT,3
MS2,9<N2EN3N64))1LN_:5?$=%4<OBNY]BR=-7#F)?S3$[@Z/>3Z@D?V=Q0.`
MC$@.9A>/?J:UR%B*Y`\W^/D7#0<6PA8B/:\/@!"-CXQNFR8,VJ091``;-F:!
M"%`>H``]=M`5:>;N.<W^G#ZB-.S99[3`W&X3EEA.1C*W4JFK4*L69RXGUT<@
MP;"J%E9M.-(<$'#=PC]0<IRORF$`$V@+TF/[U7<G46FY%J3Q*0K-\JT%<8!V
MB<BA%XBPQS:39'[B?`)BI.BE,`=2FW`=`&_0%'W_`"'3"3GO&B`;A_8/'W<'
MP#N49ZV[]#E,4>GV?:'CH"6;DMZ,.&,I<28B>XSQ-BQKG2.QI6;?$1S&^WM_
M3\DR05QE)R=3L,!,V"2CFZLZ)CE:.6Q$?IW1D^XID]P*`PST%^;<-@_)$]PQ
MRW#Q509Y%LCX*#9GT,QB)N#R@U.+*7QC;90J1'J[:;7:'%@5RH<&TD11$!V<
M`(`7$-_`=P$0$=PWW$!`1`0'W"!@']N@*"?K$5*7P[ZGN5[3(-''T-AL&-\Q
MP*RI!,A),%(J".Y\@Y0$#IMY&N.FX@&^QRB`B`[:`O@T2XQ&0Z/3;[`.D'L)
M<ZM`6B*=M3@=NX83L6UDVJB1@\2"DZ#]8;;:`-6@!H#`#W;[`(@`["/L#H'M
M^T=OM#0&#J)I%,HLH1)),IE%55#%(FFD0ICJJ'.80*1-(A=S".P`'CH"M3@F
MO<D^?O-[DCSJX^Y?HF)JGB.:=<8,&3N0L6N,K1\M5H5`PVZ:JT;_`%/6FL,Z
MD'I@56<]RQE$I,4^@!H!WW(GA/ZB/(C"N0L.9(YDX"MM2N,&=L^@6W%3\@>O
M'C%9.5ABQL^3)3L\%(?F[!+RW94E3(B&X%'0$-O^/OR%D<0<ILF<4[LLK%-,
MOQ\@:/B7HG;C$YBQ4#Q&5CA26*0I'4O`(ODC`4`,<[!,!#?0%RU(>X2&#?83
M%\?V#^OV#H#?T!$'Z@J+V.RU39H$S$;.Z(1JV<]W:F9>.G9$[I(3!U`R9)-(
MWV#KC3]X[:75CS/TK7Y&Y;!^B10MDI1?$2ZN74S>A[<.TV-Y.2VT^B3:<Y6^
M.MVYU%_-5C$^11#\<7:.C3E>RH"Y30,44H_S10"0<!L(INUD@!=&,Z@)Q)\:
M@!V@'76O7)[F!::'>QR;A>CW6SDD:U?RLN+:]:53%.E,,"\]PZ,V9'1V:4AI
MWE_*15ZE^8>G4\QO`9S-G>R"*TBY;I5Z#0((I-FW?VJO563(I@21;1S`@`4H
MAW=ZA=QWWUOKM/G7(NGWNY-1OO$=-;NAMHJ^S8US5:N5F-%2N"UX]!AJ\VS6
M1L"-=D:]555Q<OI6G2OQ!Y>9?8QZ]5*N9(L;,5A-*?*FFB0%#/U73,[Y0Y"%
M,J=KT.(FW'M*.LG?^S+:7&DL9/$V*_TJ3QW941Z.K*U%8Y*951$3BBXE,BT&
M[?-,CG2.\)<S:K7A^/X!NMRR:0K-W6IUT9V6.<*(1TD)P</(DP"8>Y%0WQ.X
MMRB`"=`P[=A@.380VUJCO7FXR.WN]N:R[WBP17)!.YWMFJM5HY]%S,15JB43
MBI>6C[<NU@;=0HC55<4IQ7KH,@MD^>1=.$R'*HD)C&,5!3<@E`!$3D`I"%#8
M@;@&P"/AKG]NS6[V[NY8K:1\KES-2N+7.=@Q&IUJJT])E_1=/5UJK):I.UBN
MKT4:E5P]!.CQWC'D/@_%T>^2,@[3J$8JLB8/C3%V4[PA3A[#>2N4=O9OK]#_
M`)>-,DT;DCMG2+ECXIV:;16N^DF9SW8\/SJFHVZ)8KK<EY=QK5J/5/4@>,@W
M^F8KI=BR'D2R15/I=4C',Q/V*;=HL8^.8-$S++*'67.0#K'*3M33+W***&`I
M"B80#6:.&!;]:XE?STEK?&\V>;/-7GG.N45)*+5@<08=K#M5%23IV-WA'*K=
M\5B<PJLS/H:(;I'.'RS+KN"]1[M`6,A`!#KX#L([#L`AX^S;X1T!7^_R(,'0
MMSXET[-QE632UX1R'&-VQW*Z#1S+5;(*B$%,Q+50YDU':S6418OBH%W$Q&ZA
MO8.@.+Z!W-2GW[C^UXI7.V,(_*F'G\BC18J:?I-GUOQC*.E92/\`R(7(I!)K
MU:0<N&JR"7QIMA0.!.SJ`%AT`$=QV-L`B(]Q3)B4NX[=W<``&P!X^`Z`HN?Y
M`=HK]EY[OTJ_,1<VK6,,4&`G0BG:+[\KFTGU@DEXES]*JN4LFBTD$3&0W[D_
M,+W[".@+H/'NT5VZX*Q%9*G.1EC@9+&M&79RT,^0?LE@2K<80_:NU663!1%=
M(Q3AT,0Y1*8-P'0%6'UY^!+G%UZ0YPX?C7$=4KC-L4,R)P?>T6I62`71/7<D
MMC-P(HS:V9X@FFY5#M(A*I$.(_/T!+AZ2WJ65?F#AV#H&3;5$1W)V@LFL+:X
MB4>-HY[D>)9MTT8S(D"V=+HG?+R34A0E&Z0"LV?$4,)`3.01`YOK)>F[(\V,
M7PV0L3L&I^0F'V<@G6X]RNW8)Y'I[\RCB5H!WRITT6[XCHOU<8=82)"Y$R1C
M%!7N*`Q[T=O4JBL41"'`?F$Y>XINV.91>NXIG,AHNJ^`,3NU!-C.W+2B:)(&
M5A7BIBQ3AP8&SMJ<J(+=Y""H!:`3,59)-9(Q%4E2$4261,"B*I#E`Q%$E""8
MATSE'<!`1`0T`3L@Y$HV**I,7O)=M@*+3:^T4?3%DLTBWBHUF@D43F$5W*A/
M-6$"[$2(!E5#B!2%,([:`A%X<<PI#U#?4OOE[Q^_L49QGXLX9G:[0HQ15]&-
M[S<<BSK"*<WNPQ`*$16,^C(AV$8@X**C9L0IQ(14YM@%W]97FK!<5.)UTJ<%
M9&K?-^:(21HU`@F3Q,;#&Q4P@=G:KL9JBI]6RCH:%4432<'*"9GJJ10$1WV`
M<IZ;V#ZOQ]X2\>,?U5\QET%:!#W&<GXPR"[6PVJ\M0L\]+&=HF.#D3.Y'R2&
M[A'RD2`/@&@'Q@'=L&W=MN(;;[AX;B&P@.X?Z:`HG>JC7W7"GU57>7\6N6C>
M0=V*A<E8./C':)3QE@?2*IK?"2""*B9F24_*Q+LXE,4I5$'^_P!W?<"Z#QSY
M#XOY0XLJ>7<366+L5<LL:R>+MF3I%24K<LL@DM)UNQL04!U%S,(Z4%!=)9,A
M@$H&*!B&*80%_P!`(9G;"E:SA5QKLX91E(,C@^K\ZW*4[J'D0*HF*@)F#M<,
MW!#=BZ)OA4+[C``A@WGSR,VQSZVBNU=?I'<1JLD,J)WVOZ$[&U1.GKP+@VYN
M6YV[J#98*Y5^DG6G57KXT(HK!PYS]5I15*+K[6TMT7&[60KLBU.1REMT4<-9
M!PV=LE?>4P'#;H`ZY`;I\DO/C:NHSV&CZ<S4K97(D4D,BO=X=<:U8E%IT5-C
M-.YF;5G1B73Y(FN:N?.U$[U,$1<RUQZ3I-,'<E4DFJ!\93Q$6@"5$A'L4`$[
MS"990`!^(=ZH#L/Z@U"T\M_F;L&PP6^@WRVT6-%HF/K/CGW5LV299&W<655Z
MSJR.'>2;Q%F3^VD^86;$&9"F7B0`0!=90`W_`#+J4"J!^W5:U+DEYI[FVM66
M^W[]+BW@6.JX)BYRX8\.\2HMR;+9)*]UU#1Z40*$EQXY)RRA2K8YFO-%%%,Z
MBKR&3$X(D!),P@,EOT(4`Z>[5KZGY8_,GK5ZV27;5\KWM1KG/6D;4ZZXK7%>
MCA0J]KO395I`UWO;5RI2C<>WK073"/!B?_/8ZR9?.R91K-=!\2GL7POGLFY;
M'\U).:>M1^C;1@*E*8R")CG4V$IC;"(:V4Y!>0+<-OKUONKF[,D=G:2>)%9L
M<KT>]**SQ*Y43*Y*\'5["R=T<VK=]M)9[?5Z2O:K<ZHB41<%IBJJJ_@)3TD_
M)3(DF4A")E*0A"@!2D(0H%*0H%*!0*4"@`````!T#PUUF@MX(HHV(U&9(T8B
M-X(U,$1/@,`RK+(J.3BYU7]OXQCN>_3HXM\G[L]N^=*Y>KXZ>DCT_P"G'F6<
MD,:(T&-;IMFR\=1HFQLZXQ<B0FZBI$`.H?<QAW'I./0D<9Z.'`FK2A)FA8WO
M&-9DJ9$QE\=9GRM4)%5$BGF`@NZB[6FLY;B<-Q3.)D]_9XZ`D[;MB-6K9HD)
MSI-$$&Z8KJ*+JG3;I%2(*JRQCJK*F*0.XQQ,8P[B81$1T!';E#TJ.&^:[9,7
M/+=8R1D&3FYZ2LJ\;9,U93>5F/DI14RSE*#K(6=.%A6)3G$$D6Z*9$2_"78.
MF@"&?T4_3A!1J[CL%/Z_),5"+,I6OY-R9%2C-=,P&(X:/V]I%=LX*)>AR"4P
M>P0T`X^P\&,(VC"U1P',R>9%\>TF6>3$2"6<\HM;6\6>_7@=C/W=O9$[/8H=
M$C\Y4FKQRJDF':`!L0-`-N;>B?Z;*`',MQ]/).ECG67?RF1LDNWZS@_WG*KL
MUI`ZJYO>(=1T`JF&?3%XD\>;O7[]AFNY#HDG7'ZDDTA(K,62C4QVX4:KM3)S
M%.=V)S7IAJ<C@PBDN@8G>4IMNXH"`#S<C8^IN7J%;L9Y!@6EFI5XA'U=M%?D
M"'!O(1,B0R"R9S$`%6Z@;>8@J00434*4Y!`0`=`1K1WHD>F[&((`VP5)DD&I
MDE&<Z7*6349]DJF!>U9I*M+0V7;KD$O=WEV.)A'<=`2!X1PE2N/U#:XWH"UM
M=5EG)2$DV_KB[V?($PW/)'(HLV3G[=(2LP>/1%(H(-C*BD@&X$``T`E7)#@[
MQ:Y:-"HYYPW4;M(I-P:M;49NXAKM'HE#Y:;*VPBL?-@DB.PE35652*(;]@Z`
M:]6/2IJ^-6A(7#',7G-B.IIE`C>G5S.2<M7V"6^_TT:WL]:EU&+5(-P(4A@$
M-]]`:LKZ.W&"_2+26S_>^2_)A^R7^I0+FG.]LFH<BOB`HP4*,#&M?B$?^F0O
MCH!W6'>%_&?CQ6[O5<$8HAL41N1HP(FY.J=(3C.P3"";-\Q:KJ6-U).YA!]'
MHR2YFZZ:I5$5#]Q1`0WT`UAUZ,OI[S3E:4M^([1?)]R4I'-CO.8<KVFP."IE
M*1,JTO)6X[I0A2EW`H_"`B.P:`7[CGP*X[<4K$K8L)1M_K95H5]!%K,AE?(=
MFH[-E(/&SU8["F6">?UYD^!5J4".$D"JID$Q2CL8=`.(RMC&N9DH%BQO;'EG
M85^SMD&TBZIMHF:79$B-GK5^D,;9ZZ[8S44<RK4"G,@J0QTS"4>@CH"/`WHM
M>G8\?NY6?PO.6Z7?G*L]F;=E;*%@EW:Q0`H'=23RUB]<G`O0!.H;;W:`-V.O
M27X38BO$%D#%%&O6.;#"3T//D"HYDRC#QDB\A7R3]FA/1*%F,PL,8=9("KM7
M9%$%TA$ARB4=M`2:Z`U5_O@.PC\(?9XCJ'B-8M'/1J=5,26]*KAQH:_;M^L1
M]HB(F#_U#MMUU!7]VD>9S>M%I^$A&V;-6=:P=2\.PQM^GZ#KQF?U/_2^8G4M
M?[!D`$.N_P"\-P_B&IE'=3_TOF'U7J8`2B/Q;E#8-NA"B/O\3;ZBB(Y<BK(C
MNK,M#RY;:M$9F7LX'R!1`P>(AUW-W#MX?\H[@'[-M2,KHID;D;E6O>S*KO53
MY2"/JM/#R]IZ:GGH(N3K.I2\>7&UHR+2)6@(%])(/GS,S]HDX03W;IK-"N&I
MEP<+B5,`[PZF]N@"-QT?Y!GL71-MR5)JR%BM[ES8DFQF2$>WA89YY9(B-:,T
M"%%%`S1(%Q\PQU!,L.X[;!H!;URN!07!H"8NO)5^F!<1!'ZCRS"B*W;\0I`I
MMW;==M`$#&`9/"L#_=P:T-M_-)#;^E"K%C`B05*$=YGG;C]7V;]^W3;;?KOH
M!1`*(AN`"(>\`$0_?H#&V@"I`WBJ6>;M%<@9A&2FJ2Z:L+2R;HN-HE\\2,LB
MU6<'1*W.X$B9A$B9S=H>.V@#8'B`"'M#IX;[^S]N@&H8CN>0;WG++S20LJ,E
MCW&S@:Q$-HN(1BFCZP/C).'/UAO/>+OG$(@B='O[R@)AW[0WVT`Z[0`_3]V@
M!MMT'H.V^WZO?]F@,]H].@]?#H/7[/?H#`]!V'H/N'H/AO\`PT!G8>G0>OAT
M'K]GOT`.TW4-AW#Q#8>F_AO[M`8T``Z^'7[.OZ>&@!^KV^[]/MT!]$^^7^8O
M\0T!O:`U5_OA_*'\1T!XZ`&@!H`:`&@!H!DO+62F[E+8XP#4TDWTM>)@ECL;
M4RJB;="KP2Y%>^452#O1BU70&.L`AN<B7:'4=`?=<@+3%\GJY"Q=\M%G9P>.
MI"1R4S>.O+JL2H_*,?48F'A&A$XZ'!8"><BA\:P(I]ZAA,;0'?Y96"U,("&J
M=6GGL?.W^59U:L0]?<+LYV2FGCE+ZF3=R"/QMJY#QHF4612[%'"RA0$X$*("
M`L4[/(X2PPO,V)\\GS4.I-2O)!\N)G<_)LFJ31(%EE#>887\D8H!W#N!3>(^
MT!G5YE+Y6L)06:;/:9P,PW6UU%Y4XAG(NVT)7F$K(IN6M4CJZ@JBQ=MCU_N!
MV=1-954Q]]P$`T`]K(]G<U+&UDMRC]&!=0U>6F%W;ALG(%;.4FQ%#-DFBJJ*
M*KA1R<$4N\>T##U`=`1L/JI-8_XWQ&;"6.TQ.9+_`'B$M)'#"6>LT9%S:90P
M,(Y_!D4)'R0JQQ3*=IDC'`%!V'8`T!))=[B-#QA-WN=[&[V#JOYJY1,)`2"8
M%@0"M"B80`0-+*%*`;^T`#0#`:E0K;"\5;??+39K%45GL;8[_'QM=?KPLC*3
MTPJ19A/6AZF0KUR=<2I)M&(&(F1$PF/WJ'#8![N,IR1K6"*=9\FR1V[R+HK&
M9M,K(J`99(A&8NQ4>'W[E'8-!3*8.IC*=/$=`()EG)MI0Q<K?7DI.TJ1NADH
MK#E`@UBLK`\>3"B;>)F;4X(1PLX6527!RHS)V-FR9BE.)E#;E`<9C>CS%!Q7
M!50)8[ZU-8<YWDY.+.I(%;*_`[MVZ=&66\]=DV>KF[$N\"^6F4H=H:`9EAN,
MR!F:YYN.ADF\M,9KS"5=_J1*74"4DI"'!0%D:N11$C:!:K.E!67^G*`IMCIM
MP$1$QP`>8A!O\<XI"')<W+MU5X%7ZF]6T1D9!-NV\UR_E71.XI73I%J4P(D,
M82"<$P-N&X"!'E7;5<D<.9>RW:[E?F%(M5@=)8YBS6-\-KL\JL+F-@DR2B8`
MHRATG!Q5<),RH`Z.B/W2%`#`=]U$Y><UK`.,YF^7!OE>RR#.3;Q\?.2"05.B
MQBZ[]_.W,Q3J*SDP[2W2(#I7RD2D\LI3'*;<"1&[W6#QW57]EGU5U6<<D@V0
M;H%*>0FI)P=-I&QL>AN4%Y"6>G*FF4-@`PB([%#?0#/<[3&1'</4J@>US$'E
MW+TPSC(&F5"2!A$4VL.%DQFUIE9)(KJ;7;L0.DN[5.1/ZCN!$I2$$1`>U78)
MO6X&%@&SARZ0@XUI&HN7RRSEZY(U;I(?4NW*YCK+.EA3$QS&$=]_U:`[A/OE
M_F+_`!#0&]H#57^^'\H?Q'0'CH`:`&@!H`:`&@&VSN';RIF>1RS3KM!PQYRJ
M,ZB^;3U=6G'T,@P5(8SJNF(^:,Q77.F`B"Y3$[A$1*;?;0"N4>@0M!CWS2+%
MVZD)E\K+6&P2:XNIRQ2RY0*I(R;P2EW.4`[$DB;)()@!2@`!H!)K?A"9N69X
MG);RZF95N%JPUZ/@&4>)9AH9V=899U&2YU@0CCRJ2OEBX33^H(F)BIF*(@(`
M*7D['47DG'=@QNZ<'CV,Q&HL$'20>>+!=DLBO'N>Q<?^Y^F<-DP4(8_>H0!Z
M^W0"?L,+R,[:J?:,F3$7-I8[9H(TFI5]DY:UQG()()H!993\P56=24IY:0`F
M3M(D@/W>[0"?\M7+NX)8YP+#.OIY7+5H1_-52`"AF-4@!,_D':Z.X"HW,Z`@
M["(`;RA#VZ`4QMB.2GIVFRF1I6(EHO&Y$3TZIP$8Y:0*<PV;$9-K',G?JK*2
M$@S:D`&R294T&YC")=Q'0!AS+C-;+M8C:BK.%AX4UGA)>QH`S,[/.Q$.Z!^I
M!D[5T0;D>N$R>8<0,``'AH#@N\66BS3\HSO-OCIK%99F)F:U0V5>)%+LTX4J
M2T=#SLH"IC2<.U>-4U_*`A16.F4#[E#;0'6SGC>0RYC:8HT1-DK;B3>0RQ'S
MAJJ\9J(Q<@B].U=-&ZB!Q:+^0!3;"`=``=`(Q/<:K59;KC6[S&3QDI:E-EB2
M;A6O)@0RPI$19GJ485T,9#_EX`84U%@74*X-YHB(@!0`<K,5YZK1I"I5N26B
M7RU?>P<7,OA7E5V#E9F+4DBY4651</5TA4$YE!-N<X[AH#D8FQQ&8HH<!1HI
MP9VG#MC"_?G1!)>8EW:JB\C,.`[CB!W[@3&`.X1`I0#?;0'/S/CE_E>DKT9K
M9!K,?,2$=_4;A-J=TYDJ^U=)N'L*@)%D!;?F78!#'Z_"`AMUT`7['A%A8K5B
MITM(H-<=XJ;"XBJ"2-*5J]GVR1&\-)/'0*>3Y,4DD!BI"F8>X3";[PZ`XS/!
M,FXS1<<J6&XB]C9YM#QT=!L6:K&38P\2LW=H0J\P"QU48I9\AYBZ;8$P=AT.
M.VX"!V<[8FL>4FM&5K5K:U22I-S8W!%R_C#33-TX9H^6@!HQ-=N591LH/<0J
MI@(([[]/`!/R<:)5QF$<GRF1WL@DXJY*])JJ1Y$[*NLX-M*GBI1-06-;8OTR
M^00C1+S$FISIE.`F%00';$(5,A$R`($3(5,@")A$"$*!2@)C"8QA`H>(B(C[
M1T!Z$^^7^8O\0T!O:`\5/+[@[]]]O9[MQT!Y_)_%H`?)_%H`?)_%H`?)_%H`
M?)_%H`?)_%H`?)_%H`?)_%H`?)_%H`?)_%H`#]/M\6^VX;[[[>(;;[?BV_;H
M!F"W]H/[_1GU7][?[P_3NORGZO\`/?I?Z?[U/K/R_P`[_P#)_IOL[O,\KIV[
M[]=`/0'R=Q\?'V>'[-NFV@,?)_%H`?)_%H`?)_%H`?)_%H`?)_%H`?)_%H`?
L)_%H`?)_%H`?)_%H`?)_%H`?)_%H`?)_%H#)?)[@V[M]PV^W?IH#9T!__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
